The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

Rebiotix, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
Clinical & Manufacturing

Rebiotix, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

FEB 10, 2020
TargEDys® Announces Positive Results of Its Clinical Trial With Its Probiotic Strain Weight Loss
Clinical & Manufacturing

TargEDys® Announces Positive Results of Its Clinical Trial With Its Probiotic Strain Weight Loss

FEB 10, 2020
Locus Biosciences initiates world’s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy
Clinical & Manufacturing

Locus Biosciences initiates world’s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy

JAN 9, 2020
Finch Therapeutics Completes Enrollment in Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
Clinical & Manufacturing

Finch Therapeutics Completes Enrollment in Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection

JAN 8, 2020
Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study
Clinical & Manufacturing

Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study

DEC 4, 2019
Preliminary Safety and Clinical Observations From 4D pharma’s Phase I/II Study of MRx0518 in Combination With KEYTRUDA®
Clinical & Manufacturing

Preliminary Safety and Clinical Observations From 4D pharma’s Phase I/II Study of MRx0518 in Combination With KEYTRUDA®

NOV 21, 2019
Group examines the unique challenges of clinical trials for development of microbiotic medicinal products, including live biotherapeutic products
Clinical & Manufacturing

Group examines the unique challenges of clinical trials for development of microbiotic medicinal products, including live biotherapeutic products

OCT 29, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with PKU
Clinical & Manufacturing

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with PKU

JUL 16, 2019
4D pharma plc Commences Phase I/II Asthma Trial
Clinical & Manufacturing

4D pharma plc Commences Phase I/II Asthma Trial

JUL 8, 2019
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
Clinical & Manufacturing

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

JUL 6, 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
Clinical & Manufacturing

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

JUN 20, 2019